A clinical overview of cholinesterase inhibitors in Alzheimer's disease

Research output: Contribution to journalReview article

71 Citations (Scopus)

Abstract

This review provides an overview of the three most widely used cholinesterase (ChE) inhibitors: donepezil, rivastigmine, and galantamine. Differences in pharmacologic profiles will be discussed, and consideration will be given to how such differences may relate to and influence the clinical efficacy and tolerability of the various agents. In addition to providing cognitive benefits in patients with Alzheimer's disease (AD), growing clinical evidence also suggests that ChE inhibitors can produce favorable and clinically relevant effects on neuropsychiatric/behavioral disturbances and activities of daily living. Furthermore, recent data indicate that these agents may be effective at all levels of disease severity and for all rates of disease progression. The clinical utility of ChE inhibitors in a wider spectrum of dementias which share a common cholinergic deficit, such as Lewy body dementia, Parkinson's disease dementia, and vascular dementia, is currently under investigation. Beyond symptomatic relief, data suggest that ChE inhibitors may also slow the underlying disease process. As clinical and research experience with these agents continues to accumulate, the differences in their effects will become more apparent and will help physicians tailor ChE inhibition treatment to the needs of the individual patient.

Original languageEnglish (US)
Pages (from-to)93-126
Number of pages34
JournalInternational Psychogeriatrics
Volume14
Issue numberSUPPL. 1
DOIs
StatePublished - Dec 1 2002

Fingerprint

Cholinesterase Inhibitors
Alzheimer Disease
Rivastigmine
Dementia
Galantamine
Lewy Body Disease
Vascular Dementia
Cholinesterases
Activities of Daily Living
Cholinergic Agents
Parkinson Disease
Disease Progression
Physicians
Research
Therapeutics

Keywords

  • Acetylcholinesterase
  • Alzheimer's disease
  • Butyrylcholinesterase
  • Dementia
  • Donepezil
  • Galantamine
  • Rivastigmine

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Aging
  • Psychiatry and Mental health
  • Psychology(all)
  • Clinical Psychology

Cite this

A clinical overview of cholinesterase inhibitors in Alzheimer's disease. / Farlow, Martin.

In: International Psychogeriatrics, Vol. 14, No. SUPPL. 1, 01.12.2002, p. 93-126.

Research output: Contribution to journalReview article

@article{a15689c63a2340dea04ed1903a764f68,
title = "A clinical overview of cholinesterase inhibitors in Alzheimer's disease",
abstract = "This review provides an overview of the three most widely used cholinesterase (ChE) inhibitors: donepezil, rivastigmine, and galantamine. Differences in pharmacologic profiles will be discussed, and consideration will be given to how such differences may relate to and influence the clinical efficacy and tolerability of the various agents. In addition to providing cognitive benefits in patients with Alzheimer's disease (AD), growing clinical evidence also suggests that ChE inhibitors can produce favorable and clinically relevant effects on neuropsychiatric/behavioral disturbances and activities of daily living. Furthermore, recent data indicate that these agents may be effective at all levels of disease severity and for all rates of disease progression. The clinical utility of ChE inhibitors in a wider spectrum of dementias which share a common cholinergic deficit, such as Lewy body dementia, Parkinson's disease dementia, and vascular dementia, is currently under investigation. Beyond symptomatic relief, data suggest that ChE inhibitors may also slow the underlying disease process. As clinical and research experience with these agents continues to accumulate, the differences in their effects will become more apparent and will help physicians tailor ChE inhibition treatment to the needs of the individual patient.",
keywords = "Acetylcholinesterase, Alzheimer's disease, Butyrylcholinesterase, Dementia, Donepezil, Galantamine, Rivastigmine",
author = "Martin Farlow",
year = "2002",
month = "12",
day = "1",
doi = "10.1017/S1041610203008688",
language = "English (US)",
volume = "14",
pages = "93--126",
journal = "International Psychogeriatrics",
issn = "1041-6102",
publisher = "Cambridge University Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - A clinical overview of cholinesterase inhibitors in Alzheimer's disease

AU - Farlow, Martin

PY - 2002/12/1

Y1 - 2002/12/1

N2 - This review provides an overview of the three most widely used cholinesterase (ChE) inhibitors: donepezil, rivastigmine, and galantamine. Differences in pharmacologic profiles will be discussed, and consideration will be given to how such differences may relate to and influence the clinical efficacy and tolerability of the various agents. In addition to providing cognitive benefits in patients with Alzheimer's disease (AD), growing clinical evidence also suggests that ChE inhibitors can produce favorable and clinically relevant effects on neuropsychiatric/behavioral disturbances and activities of daily living. Furthermore, recent data indicate that these agents may be effective at all levels of disease severity and for all rates of disease progression. The clinical utility of ChE inhibitors in a wider spectrum of dementias which share a common cholinergic deficit, such as Lewy body dementia, Parkinson's disease dementia, and vascular dementia, is currently under investigation. Beyond symptomatic relief, data suggest that ChE inhibitors may also slow the underlying disease process. As clinical and research experience with these agents continues to accumulate, the differences in their effects will become more apparent and will help physicians tailor ChE inhibition treatment to the needs of the individual patient.

AB - This review provides an overview of the three most widely used cholinesterase (ChE) inhibitors: donepezil, rivastigmine, and galantamine. Differences in pharmacologic profiles will be discussed, and consideration will be given to how such differences may relate to and influence the clinical efficacy and tolerability of the various agents. In addition to providing cognitive benefits in patients with Alzheimer's disease (AD), growing clinical evidence also suggests that ChE inhibitors can produce favorable and clinically relevant effects on neuropsychiatric/behavioral disturbances and activities of daily living. Furthermore, recent data indicate that these agents may be effective at all levels of disease severity and for all rates of disease progression. The clinical utility of ChE inhibitors in a wider spectrum of dementias which share a common cholinergic deficit, such as Lewy body dementia, Parkinson's disease dementia, and vascular dementia, is currently under investigation. Beyond symptomatic relief, data suggest that ChE inhibitors may also slow the underlying disease process. As clinical and research experience with these agents continues to accumulate, the differences in their effects will become more apparent and will help physicians tailor ChE inhibition treatment to the needs of the individual patient.

KW - Acetylcholinesterase

KW - Alzheimer's disease

KW - Butyrylcholinesterase

KW - Dementia

KW - Donepezil

KW - Galantamine

KW - Rivastigmine

UR - http://www.scopus.com/inward/record.url?scp=0036993442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036993442&partnerID=8YFLogxK

U2 - 10.1017/S1041610203008688

DO - 10.1017/S1041610203008688

M3 - Review article

C2 - 12636182

AN - SCOPUS:0036993442

VL - 14

SP - 93

EP - 126

JO - International Psychogeriatrics

JF - International Psychogeriatrics

SN - 1041-6102

IS - SUPPL. 1

ER -